Impact of bimekizumab and certolizumab pegol on efficacy, safety and osteoblastic activity in radiographic axial spondyloarthritis: results from a phase IIa, multicentre, randomised, double-blind, exploratory study with PET-CT imaging

Impact of bimekizumab and certolizumab pegol on efficacy, safety and osteoblastic activity in radiographic axial spondyloarthritis: results from a phase IIa, multicentre, randomised, double-blind, exploratory study with PET-CT imaging

Background: The efficacy and safety of bimekizumab (BKZ), an inhibitor of interleukin (IL)-17F in addition to IL-17A, has been established in axial spondyloarthritis (axSpA). Early assessment of new bone formation is possible using 18 F-fluoride positron emission tomography-computerised tomography (...

Full description

Saved in:
Bibliographic Details
Main Authors: Xenofon Baraliakos, Jerney de Jongh, Denis Poddubnyy, Gerben J. C. Zwezerijnen, Robert Hemke, Sophie Glatt, Stevan Shaw, Lucian Ionescu, Assem el Baghdady, Joanne Mann, Ralph Paul Maguire, Tom Vaux, Natasha de Peyrecave, Marga Oortgiesen, Dominique Baeten, Conny van der Laken
Format: Article
Language:English
Published: SAGE Publishing 2024-10-01
Series:Therapeutic Advances in Musculoskeletal Disease
Online Access:https://doi.org/10.1177/1759720X241293944
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1177/1759720X241293944

Similar Items